Metabolic & GLP
Research overviews of the incretin/GLP class and metabolic peptides — semaglutide, tirzepatide, retatrutide, cagrilintide, survodutide, AOD-9604, and 5-Amino-1MQ — summarizing receptor pharmacology and preclinical findings.
Semaglutide vs. Tirzepatide: How the Research Compares
Researchers studying incretin-based peptides frequently compare semaglutide and tirzepatide. This article examines what the preclinical and early clinical literature says about how these two compounds differ at the mechanistic level.
Retatrutide Research Overview: Triple-Receptor Agonism and Metabolic Science
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Here is what emerging preclinical and early clinical research has revealed about its mechanisms and metabolic effects.
GLP-1 vs. GLP-2 vs. GLP-3: How These Three Gut Peptides Differ in Structure, Receptor Biology, and Research Applications
GLP-1, GLP-2, and GLP-3 are all derived from the same proglucagon gene yet act through distinct receptors with markedly different biological roles. This article breaks down what researchers need to know about each peptide.
Cagrilintide: A Review of Amylin-Analog Research and Metabolic Mechanisms
Cagrilintide is a long-acting amylin analog studied in preclinical and clinical models for its effects on energy regulation and metabolic signaling. This overview examines the current state of laboratory and translational research.
Tirzepatide Research Overview: Dual GIP/GLP-1 Agonism and Its Mechanisms
Tirzepatide is a synthetic dual-agonist peptide that targets both GIP and GLP-1 receptors simultaneously. Researchers have investigated its metabolic signaling profile, glucose homeostasis effects, and adipose tissue dynamics across preclinical and clinical study models.
What Are GLP-1 Peptides? A Researcher's Introduction to the Incretin Class
GLP-1 peptides belong to the incretin hormone family and have become a central focus of metabolic research. This overview explains their biology, receptor pharmacology, and place in the scientific literature.
Survodutide Research: Exploring a GLP-1 / Glucagon Dual-Agonist Approach
Survodutide is a dual agonist targeting both the GLP-1 and glucagon receptors, investigated in preclinical and early clinical models for its effects on metabolic regulation. This article surveys what researchers have learned so far.
Semaglutide: A Review of the Research Literature
Semaglutide is a long-acting GLP-1 receptor agonist that has become one of the most studied compounds in metabolic and cardiovascular research. This review surveys the preclinical and clinical literature on its mechanisms and investigational findings.
5-Amino-1MQ Research: NNMT Inhibition, Metabolic Signaling, and Preclinical Findings
5-Amino-1MQ is a small-molecule NNMT inhibitor under investigation for its influence on NAD+ metabolism and fat cell biology. This overview covers what preclinical research has found and what remains to be studied.
AOD-9604: A Review of Published Preclinical Studies on This hGH Fragment
AOD-9604 is a synthetic fragment of human growth hormone studied in preclinical models for its metabolic effects. This review summarizes published findings, proposed mechanisms, and the current state of the evidence.